Susan G Hilsenbeck

发表

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials

Ying Yuan, Kenneth R Hess, Susan G Hilsenbeck, 2016, Clinical Cancer Research.

A fully Bayesian latent variable model for integrative clustering analysis of multi-type omics data.

Marina Vannucci, Cui Guo, Ronglai Shen, 2018, Biostatistics.

Patterns of resistance and incomplete response to docetaxel by gene expression profiling in breast cancer patients.

Syed Mohsin, Susan G Hilsenbeck, Michael T Lewis, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer

Veeraraghavan, Tao Wang, Chad A Shaw, 2017, Clinical Cancer Research.

GEMS (Gene Expression MetaSignatures), a Web resource for querying meta-analysis of expression microarray datasets: 17beta-estradiol in MCF-7 cells.

Neil J McKenna, David L. Steffen, Susan G Hilsenbeck, 2009, Cancer research.

Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.

Jiang Shou, Susan G Hilsenbeck, Chad J Creighton, 2008, Cancer research.

Blockade of AP-1 Potentiates Endocrine Therapy and Overcomes Resistance

Mathieu Lupien, Rinath Jeselsohn, Susan G Hilsenbeck, 2016, Molecular Cancer Research.

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.

Giovanni Parmigiani, Susan G Hilsenbeck, Judy E Garber, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Meta-analysis of multiple microarray datasets reveals a common gene signature of metastasis in solid tumors

Tsz-Kwong Man, Susan G Hilsenbeck, S. Hilsenbeck, 2011, BMC Medical Genomics.

Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.

Susan G Hilsenbeck, Jeffrey Rosen, Jian Huang, 2008, Journal of the National Cancer Institute.

Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis.

Adrian V. Lee, Susan G Hilsenbeck, Chad J Creighton, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

Syed Mohsin, Susan G Hilsenbeck, S. Hilsenbeck, 2003, The Lancet.

Reproducibility, sources of variability, pooling, and sample size: important considerations for the design of high-density oligonucleotide array experiments.

Susan G Hilsenbeck, Eun-Soo Han, S. Hilsenbeck, 2004, The journals of gerontology. Series A, Biological sciences and medical sciences.

Comprehensive Genomic Analysis Identifies Novel Subtypes and Targets of Triple-Negative Breast Cancer

Gordon B Mills, Kyle R Covington, Susan G Hilsenbeck, 2014, Clinical Cancer Research.

The promise of microarrays in the management and treatment of breast cancer

Susan G Hilsenbeck, S. Hilsenbeck, S. Fuqua, 2005, Breast Cancer Research.

Diagnostic Yield of Clinical Tumor and Germline Whole-Exome Sequencing for Children With Solid Tumors.

Tao Wang, Katie Bergstrom, Amy L McGuire, 2016, JAMA oncology.

A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models.

Chad A Shaw, Gordon B Mills, Charles M Perou, 2013, Cancer research.

A SUMOylation-Dependent Transcriptional Subprogram Is Required for Myc-Driven Tumorigenesis

Ji Luo, Chad A Shaw, Qikai Xu, 2012, Science.

The AP-1 transcription factor regulates postnatal mammary gland development.

Qiang Shen, Susan G Hilsenbeck, S. Hilsenbeck, 2006, Developmental biology.